上海莱士拟2.5亿至5亿回购股份，截至9月末已回购4.7亿元

Group 1 - The company Shanghai Laishi Blood Products Co., Ltd. announced the progress of its share repurchase plan on October 10, 2025 [1] - The repurchase plan was approved on January 13, 2025, with a total fund of no less than 250 million yuan and no more than 500 million yuan, with a maximum repurchase price of 9.55 yuan per share [2] - As of the end of September 2025, the company had repurchased a total of 70,974,175 shares at a minimum price of 6.62 yuan per share, with a total transaction amount of approximately 469.85 million yuan [3] Group 2 - The company confirmed that the repurchase complies with the established plan and relevant legal regulations, ensuring that no major events affecting the stock price occurred during the repurchase period [4] - The company will continue to advance the repurchase plan based on market conditions and will fulfill information disclosure obligations as required [4]